<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03246880</url>
  </required_header>
  <id_info>
    <org_study_id>150BPH15018</org_study_id>
    <nct_id>NCT03246880</nct_id>
  </id_info>
  <brief_title>Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase III
      Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia
      Patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean change of the total score on IPSS questionnaire(International Prostate Symptom Score )</measure>
    <time_frame>From baseline at week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean change of scores on three questionnaire, Qmax(maximum flow rate(urine), PVR(post-void residual urine volume)</measure>
    <time_frame>From baseline at week 12</time_frame>
    <description>IPSS questionnaire(International Prostate Symptom Score ), IIEF-5(International Index of Erectile Function-5) questionnaire Change in score, ICIQ-MLUTS(International Consultation on Incontinence Modular Questionnaire-Male Lower Urinary Tract Symptoms) questionnaire Change in score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change of scores on IPSS ( International Prostate Symptom Score ), ICIQ-MLUTS( International Consultation on Incontinence Modular Questionnaire-Male Lower Urinary Tract Symptoms) questionnaire Change in score</measure>
    <time_frame>From baseline at week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">455</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Tamsulosin 0.2mg+Tadalafil 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamsulosin 0.2mg+Tadalafil 5mg, po, q.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin 0.2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamsulosin 0.2mg, po, q.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tadalafil 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tadalafil 5mg, po, q.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin 0.2mg</intervention_name>
    <description>per oral for 12weeks after 2~4weeks run-in period</description>
    <arm_group_label>Tamsulosin 0.2mg+Tadalafil 5mg</arm_group_label>
    <arm_group_label>Tamsulosin 0.2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil 5mg</intervention_name>
    <description>per oral for 12weeks after 2~4weeks run-in period</description>
    <arm_group_label>Tamsulosin 0.2mg+Tadalafil 5mg</arm_group_label>
    <arm_group_label>Tadalafil 5mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        [Visit 1]

          1. Male Aged of 45 or above

          2. Patients must have a diagnosis of Benign Prostatic Hyperplasia

          3. IPSS(International Prostate Symptom Score) questionnaire total score ≥ 13

          4. Signed and dated informed consent document indicating that the patient

        [Visit 2]

          1. IPSS(International Prostate Symptom Score) questionnaire total score ≥ 13

          2. 15mL/s ≥ Qmax ≥ 4mL/s, if voided volume ≥ 120ml

          3. PVR(post-void residual urine volume) ≤ 250ml

        Exclusion Criteria:

          1. Patients have ever taken Finasteride in 3 months or Dutasteride in 6 months

          2. Patients with prostate cancer or PSA &gt; 10ng/ml

          3. Patients with other disease which could have influence on urine flow rate except
             BPH(benign prostatic hyperplasia )

          4. Patients with a history of operation on prostate which could have influence on the
             result and need to have surgery.

          5. Patients with acute urinary retention in 3months

          6. Patients with a history of drug or alcohol abuse within 6 months

          7. Patients have cardiovascular disease or associated disease which is not controlled.

          8. Patients who need to take Nitrates, alpha blocker, Nitric Oxide Donor

          9. Patients with orthostatic hypotension

         10. Patients with a history micturition syncope

         11. Patients with severe or malignant retinopathy

         12. Patients have a visual disturbance by Non-arteritic anterior ischemic optic neuropathy

         13. Patients with a congestive disease like galactose intolerance, Lapp lactase
             deficiency, glucose-galactose malabsorption

         14. Serum creatinine &gt; upper Normal Limit*2, AST/ALT &gt; upper Normal Limit*3

         15. Patient with uncontrolled diabetes(HbA1C&gt;9%)

         16. Patients have a history of malignant tumor within 5 years

         17. Patients have hypersensitivity reaction on this drug.

         18. Patients treated with other investigational product within 4 weeks at first time
             taking the investigational product

         19. Not eligible to participate for the study at the discretion of investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung-Soo Choo, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2017</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

